MUMBAI: Serum Institute of India (SII) has”revived” its need to an indemnity against possible obligations of its Covid-19 vaccine, even following media reports indicated the government is very likely to encourage a similar petition by overseas companies such as Pfizer.
Sources said a proper request from the business is expected, since it considers it is a”global standard” for vaccine makers to receive indemnity protection which waives all possible legal claims out of acute adverse events related to the disease.
Last year also, SII chief executive officer Adar Poonawalla had urged indemnity for vaccine makers that would protect them from any suits throughout the outbreak.
Thus far the government has been responsible for granting the waiver.